A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice

This study is currently recruiting participants.

Verified by AstraZeneca, November 2008

Sponsored by:	AstraZeneca
Information provided by:	AstraZeneca
ClinicalTrials.gov Identifier:	NCT00505388

Purpose

This patient follow-up programme was designed to describe the extent of Symbicort use in patients prescribed Symbicort as maintenance and reliever therapy in routine clinical practice in comparison with the already documented use of Symbicort as maintenance and reliever therapy in clinical therapies

Condition
Bronchial Asthma

MedlinePlus related topics: Asthma

Drug Information available for: Symbicort

U.S. FDA Resources

Study Type:	Observational
Study Design:	Prospective
Official Title:	A Follow-up Programme for Patients Using Symbicort SMART in Normal Clinical Practice

Further study details as provided by AstraZeneca:

Estimated Enrollment:	8000
Study Start Date:	July 2007
Estimated Study Completion Date:	August 2010
Estimated Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Asthma patients prescribed Symbicort as maintenance and reliever therapy, according to the label, before inclusion in this programme
signed and dated informed consent(ICF)
for patients under-age, signed and dated ICF form from both the patient and the patient's parent/legal guardian is required

Exclusion Criteria:

Involvement in the planning and conduct of the programme (applies to both AstraZeneca staff or staff at the investigational site)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00505388

Contacts

Contact: AstraZeneca Clinical Study, Information	1-800-236-9933	information.center@astrazeneca.com
Contact: AstraZeneca Information (Outside US)	1-800-236-9933

Show 333 Study Locations

Sponsors and Collaborators

AstraZeneca

Investigators

Study Director:	Tomas Andersson, MD	AstraZeneca
Principal Investigator:	Bjorn Stallberg, MD	Trosa Vardcentral

More Information

Related Info This link exits the ClinicalTrials.gov site

Study ID Numbers:	D5890C00018, EuDract 2006-005677-22
Study First Received:	July 17, 2007
Last Updated:	November 11, 2008
ClinicalTrials.gov Identifier:	NCT00505388
Health Authority:	Sweden: Medical Products Agency

Keywords provided by AstraZeneca:

asthma
bronchial
Symbicort

Study placed in the following topic categories:

Hypersensitivity
Lung Diseases, Obstructive
Symbicort
Respiratory Tract Diseases

Lung Diseases
Hypersensitivity, Immediate
Asthma
Respiratory Hypersensitivity

Additional relevant MeSH terms:

Respiratory System Agents
Immune System Diseases
Bronchial Diseases

Therapeutic Uses
Anti-Asthmatic Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009